SMARCB1 and cancer: A phase I clinical trial is currently recruiting to assess the safety and tolerability of CFT8634 in locally advanced or metastatic SMARCB1-Perturbed cancers including synovial sarcoma and SMARCB1-Null tumors who have been previous treated with at least one prior line of systemic therapy (ClinicalTrials.gov Identifier: NCT05355753).